OurGLP1 Newshttps://ourglp1.com/news/ Carefully sourced GLP-1 news and research updates.en-gb Muscle preservation is becoming a new focus in obesity-drug researchhttps://ourglp1.com/news/muscle-preservation-next-generation-obesity-treatmenthttps://ourglp1.com/news/muscle-preservation-next-generation-obesity-treatmentWed, 29 Jul 2026 11:00:00 GMTA Phase 2 apitegromab study and several registered trials show why obesity-drug research is looking beyond kilograms lost to lean mass, strength and physical function. GLP-1 news roundup: Retatrutide Phase 3 results, an oral approval and new eye warningshttps://ourglp1.com/news/glp1-news-roundup-retatrutide-orforglipron-naionhttps://ourglp1.com/news/glp1-news-roundup-retatrutide-orforglipron-naionWed, 29 Jul 2026 09:00:00 GMTA sourced roundup of new Retatrutide Phase 3 results, the US approval of oral orforglipron, Australian NAION warnings and an observational alcohol-hospitalisation study.